The Kenya BioVax Institute Limited’s mandate is to manufacture, package and commercialize specialized health products and technologies including vaccines, therapeutics and other biomedical products under the following objects, including but not limited to:

• Manufacture of Human Vaccines, including COVID-19 vaccines, and such other routine and emergency vaccines to serve the people of Kenya and beyond;
• Manufacture of other biomedical products including, among others, biosimilar anti-cancers, snake anti-venoms, insulin, medical infusions and such other biomedical products that can use the same platform as that of production of vaccines;
• Manufacture of pharmaceutical diagnostics and Health Products and Technologies (HPTs) including Rapid test Diagnostic Test Kits, assistive devices and specialized HPTs for cancer and gene therapy;
• Support technology transfer and commercialization of research outputs from research institutions, colleges and universities; and
• Support local pharmaceutical industries in development and production of quality and affordable products.